Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients

References

• Pippias M, Jager KJ, Kramer A, et al. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2016;31(5):831–841. doi:10.1093/ndt/gfv327
   PubMed Web of Science ®Google Scholar
• Wheeler DC, London GM, Parfrey PS, et al. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the evaluation of cinacalcet hcl therapy to lower cardiovascular events (EVOLVE) trial. J Am Heart Assoc. 2014;3(6):e001363. doi:10.1161/JAHA.114.001363
   PubMed Web of Science ®Google Scholar
• Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. JASN. 2001;12(5):1079–1084. doi:10.1681/ASN.V1251079
   Web of Science ®Google Scholar
• Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). rales investigators. Circulation. 2000;102(22):2700–2706. doi:10.1161/01.CIR.102.22.2700
   PubMed Web of Science ®Google Scholar
• Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. CJASN. 2009;4(Suppl 1):S79–S91. doi:10.2215/CJN.04860709
   PubMed Web of Science ®Google Scholar
• Mostovaya IM, Bots ML, van den Dorpel MA, et al. Left ventricular mass in dialysis patients, determinants and relation with outcome. Results from the COnvective TRansport STudy (CONTRAST). PLoS One. 2014;9(2):e84587. doi:10.1371/journal.pone.0084587
   PubMed Web of Science ®Google Scholar
• Paoletti E, Bellino D, Signori A, et al. Regression of asymptomatic cardiomyopathy and clinical outcome of renal transplant recipients: a long-term prospective cohort study. Nephrol Dial Transplant. 2016;31(7):1168–1174. doi:10.1093/ndt/gfv354
   PubMed Web of Science ®Google Scholar
• Hammer F, Malzahn U, Donhauser J, et al. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int. 2019;95(4):983–991. doi:10.1016/j.kint.2018.11.025
   PubMed Web of Science ®Google Scholar
• Sato A, Funder JW, Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens. 1999;12(9 Pt 1):867–873. doi:10.1016/S0895-7061(99)00066-7
   PubMed Web of Science ®Google Scholar
• Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol. 2007;27(2):159–163. doi:10.1159/000100106
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63(6):528–536. doi:10.1016/j.jacc.2013.09.056
   PubMed Web of Science ®Google Scholar
• Zeng Q, Zhou X, Xu G. Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: a meta-analysis. Drug Des Devel Ther. 2019;13:1487–1499. doi:10.2147/DDDT.S189454
   PubMed Web of Science ®Google Scholar
• Rossignol P, Frimat L, Zannad F. The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward. Kidney Int. 2019;95(4):747–749. doi:10.1016/j.kint.2018.12.006
   PubMed Web of Science ®Google Scholar
• Bhinder J, Patibandla S, Gupta CA, Levine A, Gass AL, Lanier GM. Mineralocorticoid receptor antagonist use in heart failure with reduced ejection fraction and end-stage renal disease patients on dialysis: a literature review. Cardiol Rev. 2020;28(3):107–115. doi:10.1097/CRD.0000000000000286
   PubMed Web of Science ®Google Scholar
• Jiang M, Bi W. The effect of aldosterone receptor antagonists on cardiovascular system in maintenance hemodialysis patients. J Clin Nephrol. 2020;20(3):239–242.
   Google Scholar
• Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep. 2003;5(5):408–417. doi:10.1007/s11906-003-0087-9
   PubMed Web of Science ®Google Scholar
• Kurdi M, De Mello WC, Booz GW. Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components. Int J Biochem Cell Biol. 2005;37(7):1357–1367. doi:10.1016/j.biocel.2005.01.012
   PubMed Web of Science ®Google Scholar
• Passier RC, Smits JF, Verluyten MJ, Daemen MJ. Expression and localization of renin and angiotensinogen in rat heart after myocardial infarction. Am J Physiol. 1996;271(3 Pt 2):H1040–H1048. doi:10.1152/ajpheart.1996.271.3.H1040
   PubMedGoogle Scholar
• Malhotra R, Sadoshima J, Brosius FC, Izumo S. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes In vitro. Circ Res. 1999;85(2):137–146. doi:10.1161/01.RES.85.2.137
   PubMed Web of Science ®Google Scholar
• Wu CK, Yang YH, Juang JJ, et al. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis. Medicine. 2015;94(3):e424. doi:10.1097/MD.0000000000000424
   PubMed Web of Science ®Google Scholar
• Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis. 2002;40(5):1023–1029. doi:10.1053/ajkd.2002.36340
   PubMed Web of Science ®Google Scholar
• Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3(9):486–492. doi:10.1038/ncpneph0575
   PubMedGoogle Scholar
• Taheri S, Mortazavi M, Shahidi S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Tran. 2009;20(3):392–397.
   PubMedGoogle Scholar
• Rahmouni K, Sibug RM, De Kloet ER, et al. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension. Eur J Pharmacol. 2002;436(3):207–216. doi:10.1016/S0014-2999(01)01586-2
   PubMed Web of Science ®Google Scholar
• Michea L, Vukusich A, González M, Zehnder C, Marusic ET. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int. 2004;66(4):1647–1653. doi:10.1111/j.1523-1755.2004.00931.x
   PubMed Web of Science ®Google Scholar
• Feniman-De-Stefano GM, Zanati-Basan SG, De Stefano LM, et al. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients. Ther Adv Cardiovasc Dis. 2015;9(4):158–167. doi:10.1177/1753944715591448
   PubMedGoogle Scholar
• Liang Y. The effects of spironolactone on LVEF and LVM in hemodialysis patients with end stage renal disease. Chin J Clin. 2011;5(18):5271–5275.
   Google Scholar
• Ziaee S, Karvandi M, Ziaee N, Ghozloujeh Z, Shahrbaf M, Roshan A. Effects of spironolactone on cardiovascular complications in hemodialysis patients of Taleghani Hospital during the period of 2016–2017: a randomized double-blind controlled clinical trial. Iranian Heart J. 2019;20(1):45–52.
   Web of Science ®Google Scholar
• Zaripova I, Kayukov I, Essaian A, Nimgirova A. Renin angiotensin aldosterone system blockade and left ventricular hypertrophy in maintenance hemodialysis patients. Nephrol Dial Transplant. 2012;27(Suppl 2):ii238.
   Google Scholar
• Charytan DM, Himmelfarb J, Ikizler TA, et al. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int. 2019;95(4):973–982. doi:10.1016/j.kint.2018.08.034
   PubMed Web of Science ®Google Scholar
• Lin C, Zhang Q, Zhang H, Long-Term LA. Effects of low-dose spironolactone on chronic dialysis patients: a randomized placebo-controlled study. J Clin Hypertens. 2016;18(2):121–128. doi:10.1111/jch.12628
   Web of Science ®Google Scholar
• Mcgill RL, Biederman RW, Getts RT. Cardiac magnetic resonance imaging in hemodialysis patients. J Nephrol. 2009;22(3):367–372.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107(20):2559–2565. doi:10.1161/01.CIR.0000068340.96506.0F
   PubMed Web of Science ®Google Scholar
• Chua D, Lo A, Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? Clin Cardiol. 2010;33(10):604–608. doi:10.1002/clc.20838
   PubMed Web of Science ®Google Scholar
• Chen KT, Kang YN, Lin YC, et al. Efficacy and safety of mineralocorticoid receptor antagonists in kidney failure patients treated with dialysis: a systematic review and meta-analysis. CJASN. 2021;16(6):916–925. doi:10.2215/CJN.15841020
   PubMed Web of Science ®Google Scholar
• Baker WL, White WB. Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. Ann Pharmacother. 2012;46(6):889–894. doi:10.1345/aph.1R011
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu Y, Cai R, et al. The safety and efficacy of low-dose mineralocorticoid receptor antagonists in dialysis patients: a meta-analysis. Medicine. 2021;100(8):e24882. doi:10.1097/MD.0000000000024882
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Nishiwaki H, Ota E, Levack WM, Noma H. Aldosterone antagonists for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2021;2(2):Cd013109. doi:10.1002/14651858.CD013109.pub2
   PubMedGoogle Scholar
• Roehm B, Gulati G, Weiner DE. Heart failure management in dialysis patients: many treatment options with no clear evidence. Semin Dial. 2020;33(3):198–208. doi:10.1111/sdi.12878
   PubMed Web of Science ®Google Scholar
• Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022;179(13):3220–3234. doi:10.1111/bph.15747
   PubMed Web of Science ®Google Scholar
• Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases. Drug Dev Res. 2021;82(3):341–363. doi:10.1002/ddr.21760
   PubMed Web of Science ®Google Scholar
• Capelli I, Gasperoni L, Ruggeri M, et al. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J Nephrol. 2020;33(1):37–48. doi:10.1007/s40620-019-00600-7
   PubMed Web of Science ®Google Scholar
• Walsh M, Manns B, Garg AX, et al. The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial. CJASN. 2015;10(9):1602–1608. doi:10.2215/CJN.12371214
   PubMed Web of Science ®Google Scholar
• Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment. Clin Pharmacol Drug Dev. 2016;5(6):488–501. doi:10.1002/cpdd.263
   PubMed Web of Science ®Google Scholar
• Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453–2463. doi:10.1093/eurheartj/eht187
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884–894. doi:10.1001/jama.2015.10081
   PubMed Web of Science ®Google Scholar